MWI Animal Health acquires Northeast Veterinary Supply CompanyDecember 13, 2017MWI Animal Health, a part of AmerisourceBergen, has acquired Northeast Veterinary Supply Co. (NEVSCO), an independent, regional distributor of veterinary pharmaceuticals and medical supplies servicing primarily the northeast region of the US. The acquisition of NEVSCO continues to strengthen MWI's position to better support the viability of independent veterinary practices and provide even greater value and care to current and future animal health customers, according to the company. The acquisition of NEVSCO bolsters MWI's presence and capabilities in the northeast region of the US, as the increased scale enables the company to improve access, increase supply chain efficiency, and enhance care in the companion and production animal space, said the company in a statement. The move also better positions MWI to help independent veterinary practices navigate mounting industry challenges and thrive in today's healthcare environment, the company stated. NEVSCO customers will have access to an expanded product portfolio, as well as MWI's industry e-commerce platform and practice building programs, and customers' businesses will benefit from NEVSCO's enhanced high-touch, consultative service model, which now features expanded product access, MWI stated. Visti mwiah.com for more information.
SPONSORED CONTENTYour Parasite Protection Recommendation, SimplifiedManaging parasite prevention doesn’t have to be complicated. Discover a single solution that protects against multiple threats. + Learn More
MWI Animal Health, Securos Surgical invest in Serene LLCOctober 3, 2017MWI Animal Health and Securos Surgical, both a part of AmerisourceBergen, announced they have invested in the emerging pipeline of Serene LLC and will negotiate a distribution partnership with its veterinary subsidiary, Convetra Inc. "This investment by MWI and Securos is an important validation of the potential of our tin-117m in the veterinary marketplace," said Dennis Steadman, board director of Serene LLC. The proprietary tin-117m therapies being developed by Serene and Convetra are targeted to treat a variety of medical conditions afflicting companion animals, horses, and humans, according to MWI Animal Health. Convetra is currently conducting trials in canine osteoarthritis (OA) using tin-117m in a therapeutic approach called radiosynoviorthesis, the company stated. In the U.S., an estimated 20 percent of dogs one year of age or older—or about 16 million—are afflicted with some degree of OA, according to the company.
